Temozolomide analog PMX 465 downregulates MGMT expression in HCT116 colorectal carcinoma cells

被引：2

作者：

Yang, Zhikuan ^{[1
]}

Wei, Danping ^{[1
]}

Liu, Feifei ^{[1
]}

Liu, Jing ^{[1
]}

Wu, Xiaoming ^{[1
]}

Stevens, Malcolm F. G. ^{[2
]}

Bradshaw, Tracey D. ^{[2
]}

Luo, Ying ^{[1
]}

Zhang, Jihong ^{[1
]}

机构：

[1] Kunming Univ Sci & Technol, Med Sch, Kunming, Yunnan, Peoples R China

[2] Univ Nottingham, Ctr Biomol Sci, Nottingham, England

来源：

JOURNAL OF CELLULAR BIOCHEMISTRY | 2018年 / 119卷 / 07期

基金：

中国国家自然科学基金;

关键词：

colorectal carcinoma; O6-methylguanine-DNA methyltransferase; PMX; 465; p53; Sp1; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE MGMT; SP1 TRANSCRIPTION FACTOR; GLIOBLASTOMA CELLS; GENE-EXPRESSION; GLIOMA-CELLS; REPAIR; TARGET; CANCER; RESISTANCE; PROTEINS;

D O I：

10.1002/jcb.26674

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The efficacy of temozolomide (TMZ) treatment for cancers is currently limited by inherent or the development of resistance, particularly, but not exclusively, due to the expression of the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) in a significant proportion of tumors. We have found that TMZ analog C8-methyl imidazole tetrazine (PMX 465) displayed good anticancer activity against the colorectal carcinoma HCT116 cells which are MGMT-overexpressing and mismatch repair (MMR)-deficient. In this study, we found that PMX 465 could downregulate the expression of MGMT in HCT116 cells at the protein and mRNA levels. We found that PMX 465 could reduce MGMT expression by increasing the binding of wild-type p53 to the MGMT promoter and reducing the binding of Sp1 to the MGMT promoter.

引用

页码：5350 / 5358

页数：9

共 22 条

[11] Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer [J].

Nakagawachi, T ;

Soejima, H ;

Urano, T ;

Zhao, W ;

Higashimoto, K ;

Satoh, Y ;

Matsukura, S ;

Kudo, S ;

Kitajima, Y ;

Harada, H ;

Furukawa, K ;

Matsuzaki, H ;

Emi, M ;

Nakabeppu, Y ;

Miyazaki, K ;

Sekiguchi, M ;

Mukai, T .

ONCOGENE, 2003, 22 (55) :8835-8844

[12]

Natsume A, 2005, CANCER RES, V65, P7573, DOI 10.1158/0008-5472.CAN-05-0036

[13] Glioblastoma Multiforme Therapy and Mechanisms of Resistance [J].

Ramirez, Yulian P. ;

Weatherbee, Jessica L. ;

Wheelhouse, Richard T. ;

Ross, Alonzo H. .

PHARMACEUTICALS, 2013, 6 (12) :1475-1506

[14] Transcription factor Sp1, also known as specificity protein 1 as a therapeutic target [J].

Safe, Stephen ;

Imanirad, Parisa ;

Sreevalsan, Sandeep ;

Nair, Vijayalekshmi ;

Jutooru, Indira .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (07) :759-769

[15] Disruption of NF-κB signaling by fluoxetine attenuates MGMT expression in glioma cells [J].

Song, Tao ;

Li, Hui ;

Tian, Zhiliang ;

Xu, Chaojiu ;

Liu, Jingfang ;

Guo, Yong .

ONCOTARGETS AND THERAPY, 2015, 8 :2199-2208

[16] Sp1 transcription factor: A long-standing target in cancer chemotherapy [J].

Vizcaino, Carolina ;

Mansilla, Sylvia ;

Portugal, Jose .

PHARMACOLOGY & THERAPEUTICS, 2015, 152 :111-124

[17] Bortezomib Downregulates MGMT Expression in T98G Glioblastoma Cells [J].

Vlachostergios, Panagiotis J. ;

Hatzidaki, Eleana ;

Stathakis, Nikolaos E. ;

Koukoulis, George K. ;

Papandreou, Christos N. .

CELLULAR AND MOLECULAR NEUROBIOLOGY, 2013, 33 (03) :313-318

[18] A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study [J].

Warren, Katherine E. ;

Gururangan, Sri ;

Geyer, J. Russell ;

McLendon, Roger E. ;

Poussaint, Tina Young ;

Wallace, Dana ;

Balis, Frank M. ;

Berg, Stacey L. ;

Packer, Roger J. ;

Goldman, Stewart ;

Minturn, Jane E. ;

Pollack, Ian F. ;

Boyett, James M. ;

Kun, Larry E. .

JOURNAL OF NEURO-ONCOLOGY, 2012, 106 (03) :643-649

[19] 3-aminobenzamide and/or O-6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O-6-alkylguanine-DNA alkyltransferase activity [J].

Wedge, SR ;

Porteous, JK ;

Newlands, ES .

BRITISH JOURNAL OF CANCER, 1996, 74 (07) :1030-1036

[20]

Yang Z, 2017, NEUROONCOL OPEN ACCE, V1, P1

← 1 2 3 →